My last blog on ultrasound and fracture healing brought up
the topic of authors with conflicts of interest. This is where the authors have
something to gain from publishing favourable results of medical therapies;
benefits that might include royalties, stock options, research funding and my
favourite: consultancy fees (this is fancy term for a relatively simple process whereby a
company gives money to a doctor, often large amounts and at regular intervals).
Sometimes the authors are direct employees of the company making the device or
drug in question. And sometimes these employees write the article for the
esteemed senior author to put his or her name to (ghost writing), thereby
giving the article authority.
But does the presence of conflict of interest influence
whether or not the study is actually favourable – does it bias reporting? I
could list examples where sponsored studies show a benefit, and independent
studies do not, like in my last blog. But I am probably biased myself, and my
recollection or perception does not represent scientific evidence of conflict
of interest causing bias in reporting. This, however,
does. And this. And this. In fact, I
can’t remember the last time I read a sponsored study that was not favourable for the product in
question.
Why does a conflict of interest lead to biased (one-sided)
reporting of results? Because of what I call a Concordance of Interests. A
favourable study supports the interests of all parties involved, as follows:
1.
It is in the interest of the surgeons writing
the article, often because they are getting paid (directly or indirectly) by the producer, or because it
justifies the surgery by which they earn a living
2.
It is in the interest of the company paying for
the study as it will sell more of the product.
3.
It is in the interest of the publishing journal,
as positive studies are more newsworthy and more likely to be referenced (therefore
raising the impact factor of the journal).
Unfortunately, the outlook is not so good, as more and more
studies are being conducted by the manufacturing companies themselves (rather
than paying others to do them, they are keeping it more “in-house”). This not
only gives them control over the study, but control over whether or not to
publish the results. Guess which ones
they publish? A good example of this is with antidepressant drugs. Reviewing
all published trials would lead you to conclude that antidepressants are more
effective than placebos. In a study
by Irving Kirsch, he looked at this by gaining access to all of the studies
performed (not just the one that were published: he managed to get access to
the unpublished ones held back by the manufacturers, using the Freedom of
Information Act). When he summarised the data from all studies performed
(published or not), he found that the antidepressant drugs were no better than
placebo except for the most severe cases, where their effect was marginal. Yet
these drugs are still being used today. Commonly, and for depression of any
severity.
I have worse news: the authorities feel that the problem is
now solved because of the strict rules that now apply regarding the declaration
of a conflict of interest that doctors must make when publishing or presenting
research. The objection I have is that declaring a conflict of interest does
not remove it. It might lead the reader to be more wary, but it doesn’t change
the fact that the conflict exists. It’s like fixing your leaking tap by
recording how much water is coming out of it.
Addit 28 July 2012: Former editor of BMJ on conflict of interest, here.
Addit 28 July 2012: Former editor of BMJ on conflict of interest, here.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.